Haemonetics Director Robert Abernathy Receives RSU Award

What Happened Robert E. Abernathy, a director of Haemonetics Corporation (HAE), was awarded 2,538 restricted stock units (RSUs) on July 24, 2026 (transaction code A — award/grant). No per-share price or immediate cash value is reported (N/A). These RSUs are compensation — not an open-market purchase or sale — and will convert to common shares when they vest.

Key Details

• Transaction date: 2026-07-24; Form 4 filed 2026-07-28 (timely filing).
• Award: 2,538 RSUs; price per share: N/A; total reported value: N/A.
• Vesting: RSUs vest 100% on the first anniversary of the grant (per footnote).
• Each RSU represents a contingent right to one share of common stock upon vesting (per footnote).
• Shares owned after the transaction: not specified in the filing.
• No tax-withholding, sale, or 10b5-1 plan noted in the filing.

Context RSU awards are a common form of executive/director compensation and generally reflect long-term incentive pay rather than an immediate market bet. These RSUs will only convert into actual shares (and potentially be sellable) once they vest on the one-year anniversary.